Advertisement

 

 

Fixed dose combination emtricitabine/tenofovir/efavirenz initiated during Acute HIV Infection; 96-week efficacy and durability.

Fixed dose combination emtricitabine/tenofovir/efavirenz initiated during Acute HIV Infection; 96-week efficacy and durability.
Author Information (click to view)

Gay CL, Willis SJ, Cope AB, Kuruc JD, Mcgee KS, Sebastian J, Crooks AM, Mckellar MS, Margolis DM, Fiscus SA, Hicks CB, Ferrari G, Eron JJ, ,


Gay CL, Willis SJ, Cope AB, Kuruc JD, Mcgee KS, Sebastian J, Crooks AM, Mckellar MS, Margolis DM, Fiscus SA, Hicks CB, Ferrari G, Eron JJ, , (click to view)

Gay CL, Willis SJ, Cope AB, Kuruc JD, Mcgee KS, Sebastian J, Crooks AM, Mckellar MS, Margolis DM, Fiscus SA, Hicks CB, Ferrari G, Eron JJ, ,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

AIDS (London, England) 2016 9 20()

Abstract
BACKGROUND
Updated guidelines recommend immediate antiretroviral treatment (ART) during acute HIV infection (AHI), but efficacy data on regimens during AHI are limited.

METHODS
We provide final data on a prospective, single-arm 96-week open label study of once daily emtricitabine/tenofovir/efavirenz initiated during AHI. The primary endpoint was the proportion of responders with HIV RNA <200 copies/mL by week 24. We examined time-to-viral-suppression, retention and CD8 cell activation through week 96 in relation to baseline characteristics. RESULTS
Between January 2005 and December 2011, 92 AHI participants enrolled. Most participants (78%) were MSM, and 42% were young MSM (18-25 years of age). Two participants withdrew leaving 90 patients for analysis. Eighty-one (90%) remained on therapy and achieved viral suppression to <200 copies/mL by week 24, and 71 (79%) to <50 copies/mL at week 48. The median time from ART initiation to suppression <200 copies/mL was 65 days (range 7-523) and to <50 copies/mL was 105 days (range 14-523). The frequency of immune activation declined from a median of 67% to 16% through week 96. Retention on study was maintained in 92% of participants at week 48 and in 83% through week 96. Among 75 participants retained through week 96, 92% were suppressed to <50 copies/mL. Among 39 young MSM, 79% completed a week 96 visit and 67% were suppressed at week 96. CONCLUSION
ART during AHI resulted in rapid and sustained viral suppression with high rates of retention in care and on ART in this cohort including a large proportion of young MSM.

Submit a Comment

Your email address will not be published. Required fields are marked *

six − 6 =

[ HIDE/SHOW ]